Haemonetics (NYSE: HAE) reported Q4 EPS of $0.43, $0.01 better than the analyst estimate of $0.42. Revenue for the quarter came in at $233.6 million versus the consensus estimate of $227.12 million.

GUIDANCE:

Haemonetics sees FY2019 EPS of $2.00-$2.30, versus the consensus of $2.09.

For earnings history and earnings-related data on Haemonetics (HAE) click here.